Schrödinger, Inc. (NASDAQ:SDGR) EVP Yvonne Tran sold 10,000 shares of the company’s stock in a transaction dated Monday, February 22nd. The shares were sold at an average price of $113.66, for a total transaction of $1,136,600.00. Following the transaction, the executive vice president now owns 26,731 shares in the company, valued at approximately $3,038,245.46. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of NASDAQ:SDGR traded down $3.51 during trading on Tuesday, hitting $108.87. The company’s stock had a trading volume of 1,450,092 shares, compared to its average volume of 763,750. The company has a 50-day moving average of $95.77 and a 200-day moving average of $70.53. Schrödinger, Inc. has a 12 month low of $27.04 and a 12 month high of $117.00.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SDGR. BlackRock Inc. raised its stake in Schrödinger by 93.8% during the 3rd quarter. BlackRock Inc. now owns 2,007,517 shares of the company’s stock worth $95,376,000 after acquiring an additional 971,766 shares during the period. Bamco Inc. NY raised its stake in Schrödinger by 63.6% during the 4th quarter. Bamco Inc. NY now owns 1,694,734 shares of the company’s stock worth $134,189,000 after acquiring an additional 658,523 shares during the period. Bain Capital Public Equity Management II LLC bought a new stake in Schrödinger during the 3rd quarter worth approximately $27,596,000. Amundi Pioneer Asset Management Inc. raised its stake in Schrödinger by 17,064.3% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 532,094 shares of the company’s stock worth $42,130,000 after acquiring an additional 528,994 shares during the period. Finally, Blackstone Group Inc bought a new stake in Schrödinger during the 3rd quarter worth approximately $22,975,000. Institutional investors own 41.29% of the company’s stock.
Schrödinger Company Profile
SchrÃ¶dinger, Inc provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries.
See Also: Why do earnings reports matter?
Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.